• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    5/30/24 4:31:17 PM ET
    $ABEO
    $ADAP
    $ARAY
    $COSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABEO alert in real time by email

    Gainers

    • MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 12.83% to $0.33.
    • BiomX (AMEX:PHGE) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million.
    • Virios Therapeutics (NASDAQ:VIRI) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million.
    • Accuray (NASDAQ:ARAY) stock increased by 5.73% to $1.66. The company's market cap stands at $164.7 million.

    Losers

    • Veeva Systems (NYSE:VEEV) stock fell 7.8% to $179.0 during Thursday's after-market session. The company's market cap stands at $28.9 billion. The company's, Q1 earnings came out today.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares fell 6.64% to $2.23. The company's market cap stands at $6.9 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock decreased by 6.6% to $0.23. The market value of their outstanding shares is at $5.4 million.
    • OneMedNet (NASDAQ:ONMD) stock decreased by 6.14% to $2.45. The company's market cap stands at $58.4 million.
    • Cosmos Health (NASDAQ:COSM) stock fell 5.0% to $0.66. The market value of their outstanding shares is at $11.0 million.
    • Abeona Therapeutics (NASDAQ:ABEO) stock fell 4.99% to $4.0. The company's market cap stands at $164.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $ADAP
    $ARAY
    $COSM

    CompanyDatePrice TargetRatingAnalyst
    Veeva Systems Inc.
    $VEEV
    2/17/2026$205.00Underweight → Equal-Weight
    Morgan Stanley
    Veeva Systems Inc.
    $VEEV
    1/13/2026$215.00Sell
    Goldman
    Veeva Systems Inc.
    $VEEV
    1/8/2026Hold → Buy
    Truist
    Veeva Systems Inc.
    $VEEV
    12/12/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Veeva Systems Inc.
    $VEEV
    11/13/2025$300.00Market Perform
    BMO Capital Markets
    Veeva Systems Inc.
    $VEEV
    10/7/2025$380.00Hold → Buy
    TD Cowen
    Veeva Systems Inc.
    $VEEV
    9/8/2025$330.00Neutral → Overweight
    Analyst
    Adaptimmune Therapeutics plc
    $ADAP
    7/29/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Boyages Steven Constantine

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:35 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Hurd Jonathan Scott

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:31 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Sakiris Spiro Kevin

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:32 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ABEO
    $ADAP
    $ARAY
    $COSM
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    3/27/26 4:50:53 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Veeva Systems Inc.

    SCHEDULE 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    3/27/26 1:51:01 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Accuray Incorporated

    SCHEDULE 13G/A - ACCURAY INC (0001138723) (Subject)

    3/26/26 3:05:49 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Veeva Systems upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Veeva Systems from Underweight to Equal-Weight and set a new price target of $205.00

    2/17/26 8:05:30 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Goldman resumed coverage on Veeva Systems with a new price target

    Goldman resumed coverage of Veeva Systems with a rating of Sell and set a new price target of $215.00

    1/13/26 9:18:31 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Veeva Systems upgraded by Truist

    Truist upgraded Veeva Systems from Hold to Buy

    1/8/26 9:27:19 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

    NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the "Company Guide"), requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity

    3/27/26 4:30:00 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

    NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance its 2026 operations with over $3 million from internal funds, including for operations and acquisitions related to security, defense and first response. For its initial transaction, BiomX has signed a non-binding LOI with an unrelated third party to secure the exclusive distribution rights in Israel for an advanced aerial firefighting system from a drone components and payload developer. The proposed license would grant X Security & Defense the rights to distribute drone-based fire suppression solutions,

    3/26/26 8:48:01 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent, further enhancing intellectual property rights around its fingerprint sweat drug testing technology. The newly granted patent protects a key advancement in how the Company's technology analyzes substances detected in fingerprint sweat by correlating chemical findings with the volum

    3/26/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ABEO
    $ADAP
    $ARAY
    $COSM
    Financials

    Live finance-specific insights

    View All

    Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

    - First ZEVASKYN® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the full year of 2025 and recent operational progress. "2026 is about building a steady cadence of biopsies and treatments," said Vish Seshadri, Chief Executive Officer of Abeona. "We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us

    3/17/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veeva Acquires Ostro, the Leading Brand Engagement Platform for Life Sciences

    PLEASANTON, Calif., March 10, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience. Ostro-powered brand websites allow customers to easily ask questions and receive approved information, resources, and next steps in real-time. Leveraging this rich engagement data, Ostro also generates deep insights brands use to improve reach and engagement.Ostro utilizes a combination of conversa

    3/10/26 11:45:00 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Veeva Announces Fourth Quarter and Fiscal Year 2026 Results

    Fiscal Year 2026 Total Revenues of $3,195.3M, up 16% Year Over YearQ4 Total Revenues of $836.0M, up 16% Year Over YearFiscal Year 2026 Subscription Revenues of $2,684.2M, up 17% Year Over YearQ4 Subscription Revenues of $707.7M, up 16% Year Over YearPLEASANTON, Calif., March 4, 2026 /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2026. "The agentic transformation underway represents a substantial opportunity for Ve

    3/4/26 4:05:00 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology